Global Subcutaneous Immunoglobulin (SCIG) Market Trends: Regional Breakdowns and Strategic Insights
Discover trends, market shifts, and competitive outlooks for the subcutaneous immunoglobulin (scig) industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
What Are the Projected Market Size and Growth Rates for the Subcutaneous Immunoglobulin (SCIG) Market From 2025 To 2029?
Recent years have seen a swift expansion in the subcutaneous immunoglobulin (SCIG) market size. The market, predicted to rise from $12.72 billion in 2024 to $14.52 billion in 2025, boasts a compound annual growth rate (CAGR) of 14.1%. The substantial growth during the historical period is a consequence of various factors including a surge in immunodeficiency disorders, an increase in patients opting for home-based care, improved therapeutic efficacy, greater awareness and diagnosis rates, and advantageous reimbursement policies.
In the forthcoming years, the market for subcutaneous immunoglobulin (SCIG) is poised for rapid expansion. The market is slated to reach $24.29 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 13.7%. Several factors will underpin this growth in the forecast period, such as expanding incidence of neurological disorders and autoimmune diseases, augmented awareness and acceptance of immunoglobulin treatment, broadening usage in the fields of neurology and dermatology, and enhanced healthcare infrastructure. Key trends during the forecast period will include progress in drug delivery systems, rising demand for therapies involving home infusion, advancements in antibody treatment, formulation innovations, and advances in SCIG.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15935&type=smp
What Are the Core Market Drivers Propelling Growth in the Subcutaneous Immunoglobulin (SCIG) Industry?
The surge in secondary immunodeficiency diseases is expected to stimulate the expansion of the subcutaneous immunoglobulin market in the future. These disorders, which stem from factors other than the immune system itself, weaken the immune system. Contributing factors to the prevalence of secondary immunodeficiency diseases include aging demographics, the use of immunosuppressive treatments, and environmental contaminants. Subcutaneous immunoglobulin therapy, which provides antibodies to bolster the compromised immune system, is particularly valuable in managing chronic disorders such as HIV and autoimmune diseases, as it prevents infections and aids in immunological function during treatment. For instance, the UK Health Security Agency, a UK government agency, reported a 22% increase in new HIV diagnoses in England in 2022, with a total of 3,805 cases noted in October 2023. As a result, the growing prevalence of secondary immunodeficiency diseases is spurring the growth of the subcutaneous immunoglobulin market. The surge in neurological disorders is another significant catalyst expected to fuel the expansion of the subcutaneous immunoglobulin market. Neurological disorders refer to any disorders related to the nervous system, including abnormalities in the brain, spinal cord, or peripheral nerves brought about by conditions like acute spinal cord injury, Alzheimer’s dementia, Amyotrophic Lateral Sclerosis (ALS), ataxia, brain tumors, and more. The rise in neurological disorders can be attributed to factors such as aging demographics, environmental pollutants, genetic factors, and lifestyle modifications. Subcutaneous immunoglobulin therapy comes in handy in managing neurological disorders as it provides antibodies that modulate the immune response, diminish inflammation, and stabilize neuromuscular junctions, potentially slowing disease progression and enhancing symptom management. For instance, the Alzheimer’s Association, a US-based nonprofit health organization, reported in March 2022 that there were 6.5 million Americans aged 65 and above living with Alzheimer’s dementia, a figure that is projected to hit 13.8 million by 2060. Therefore, the rise in neurological disorders is triggering the growth of the subcutaneous immunoglobulin market.
Which Key Market Segments Comprise the Subcutaneous Immunoglobulin (SCIG) Market and Drive Its Revenue Growth?
The subcutaneous immunoglobulin (SCIG) market covered in this report is segmented –
1) By Product Type: Immunoglobulin A (IgA), Immunoglobulin G (IgG), Immunoglobulin M (IgM)
2) By Application: Primary Immunodeficiency Disorders, Autoimmune Diseases, Neurological Disorders, Other Applications
3) By End-Use: Clinics, Hospitals, Homecare, Other End-Uses
Subsegments:
1) By Immunoglobulin A (IgA): IgA1, IgA2
2) By Immunoglobulin G (IgG): IgG1, IgG2, IgG3, IgG4
3) By Immunoglobulin M (IgM): Pentameric IgM, Hexameric IgM
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=15935&type=smp
Which Regions Are Driving the Next Phase of the Subcutaneous Immunoglobulin (SCIG) Market Growth?
North America was the largest region in the subcutaneous immunoglobulin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the subcutaneous immunoglobulin (SCIG) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Are the Strategic Trends Steering the Subcutaneous Immunoglobulin (SCIG) Market Direction?
Prominent players in the subcutaneous immunoglobulin market are involved in the creation of subcutaneous human-klhw, an exclusive blend composed of human immune globulins (Ig) designed to reinforce the immune system. This formulation is intended to be administered subcutaneously to treat primary immunodeficiency diseases in humans. An example of this is when Grifols S.A., a pharmaceutical company from Spain, unveiled XEMBIFY 20% subcutaneous immunoglobulin (SCIG) in March 2022. This solution has been made explicitly for treating primary immunodeficiency, thus fulfilling a considerable medical necessity for those with compromised immune systems. XEMBIFY offers a ready-made formulation that streamlines the treatment procedures, enhancing patient convenience. It can remain stable at room temperature up to 24 months, eliminating the requirement for refrigeration during its storage or transportation. This makes it highly convenient in various healthcare conditions.
View the full report here:
How Is the Subcutaneous Immunoglobulin (SCIG) Market Conceptually Defined?
Subcutaneous immunoglobulin (SCIG) refers to a method of administering immunoglobulin therapy in which the medication is delivered under the skin, rather than into a vein. This method allows for slower absorption of the medication, reducing the risk of side effects compared to intravenous administration. SCIG is used to treat various immune deficiencies, providing a convenient and effective way to boost the immune system.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15935
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
